Genocea Biosciences Inc. Stock
-
Your prediction
Genocea Biosciences Inc. Stock
Genocea Biosciences (Symbol GNCA) (WKN A2PK76) is a publicly traded, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel vaccines and immunotherapies for various infectious diseases and cancer. With a unique approach to unlocking the power of T-cells in rapid vaccine and immunotherapy discovery, the company has established a robust pipeline targeting a wide spectrum of viral, bacterial, and parasitic diseases as well as oncology indications. Notable programs include GEN-003 for genital herpes and GEN-009, an innovative and personalized neoantigen cancer vaccine. Listed on the Nasdaq stock exchange, Genocea is dedicated to improving patient outcomes through cutting-edge research, expertise in immune targeting, and a strong commitment to scientific innovation.
Pros and Cons of Genocea Biosciences Inc. in the next few years
Pros
Cons
Performance of Genocea Biosciences Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Genocea Biosciences Inc. | - | - | - | - | - | - | - |
| Evolus Inc | -2.150% | -3.417% | 3.222% | -27.925% | 5.798% | -11.969% | -44.019% |
| Heron Therapeutics Inc. | -4.440% | 0.915% | 5.753% | -80.294% | -66.338% | -68.750% | -96.867% |
| Rhythm Pharmaceuticals | -1.580% | -3.553% | 25.828% | 27.517% | 1.604% | 573.759% | 479.268% |
Comments
